Abstract 1202
Background
Nivolumab can cause immune-related adverse events requiring caution, including ILD.
Methods
Clinical and chest imaging findings for each ILD case reported by nivolumab-treated patients with NSCLC were assessed by the ILD Expert Central Review Committee. ILD prognosis was evaluated by radiographic findings, including the presence/absence of peritumoral infiltration (PTI), a characteristic of nivolumab-induced ILD. Poor prognostic factors were identified by multivariate Cox regression analysis.
Results
Of patients reported by physicians from December 2015 to March 2016, 325 nivolumab-treated patients with NSCLC assessed for ILD, 238 patients had nivolumab-induced ILD. The main radiographic patterns of ILD were cryptogenic organizing pneumonia/chronic eosinophilic pneumonia-like (127/238 patients, 53.4%), faint infiltration pattern/acute hypersensitivity pneumonia-like (48/238 patients, 20.2%), diffuse alveolar damage (DAD) (26/238 patients, 10.9%), and nonspecific interstitial pneumonia-like (fibrosing organizing pneumonia) (15/238 patients, 6.3%). The ILD mortality rate was 65.4% in patients with DAD pattern and 4.2% to 13.6% in patients with the other patterns. The ILD mortality rate was 11.1% in the 27 patients with PTI and 16.3% in the 209 patients without PTI. The antitumor response was as follows: partial response: 34.0%; stable disease: 33.6%; and progressive disease: 21.4% patients. In 5 of the 37 patients who died due to ILD, the radiographic pattern changed to DAD pattern from other patterns at onset. Multivariate Cox regression analysis identified 5 factors for poor prognosis of ILD: DAD pattern; ≤60 days from start of nivolumab treatment to onset of ILD; pleural effusion present before treatment; abnormal opacities distributed contralateral or bilateral to the tumor; and abnormal change in C-reactive protein level.
Conclusions
Patients with NSCLC with these factors for poor prognosis of nivolumab-induced ILD should be monitored for ILD during nivolumab treatment.
Clinical trial identification
Editorial acknowledgement
Medical writing assistance was provided by Justine Southby, PhD, CMPP, and Hiroko Ebina, BPharm, Ph, MBA, of ProScribe – Envision Pharma Group, and was funded by Ono Pharmaceutical Co., Ltd.
Legal entity responsible for the study
Ono Pharmaceutical Co., Ltd.
Funding
Ono Pharmaceutical Co., Ltd., Osaka, Japan, and Bristol-Myers Squibb K.K., Tokyo, Japan.
Disclosure
K. Oikado: Honoraria (self): Ono Pharmaceutical ; Honoraria (self): AstraZeneca. Y. Saito: Honoraria (self): Ono Pharmaceutical Co., Ltd.; Honoraria (self): Boehringer Ingelheim Co., Ltd.; Honoraria (self): Novartis Pharma K.K.; Honoraria (self): AstraZeneca K.K.; Honoraria (self): Chugai Pharma Co., Ltd.; Honoraria (self): MSD K.K. J. Tominaga: Honoraria (self): Ono Pharmaceutical . M. Sata: Honoraria (self): Ono Pharmaceutical Company. F. Sakai: Honoraria (self): Ono Pharmaceutical ; Honoraria (self): AstraZeneca Co., Ltd.; Honoraria (self): Boehringer Ingelheim Co., Ltd.; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Merck Serono Co., Ltd; Research grant / Funding (institution): Bayer Co., Ltd.; Research grant / Funding (institution): Eisai Co., Ltd.; Honoraria (self): Shionogi Pharmaceuticals Co., Ltd.; Research grant / Funding (institution): Fuji Pharmaceuticals Co., Ltd.; Honoraria (self), Research grant / Funding (institution): Daiichi Pharmaceuticals; Research grant / Funding (institution), Non-remunerated activity/ies: Toshiba; Honoraria (self), Research grant / Funding (institution): Japanese Ministry of Labour, Health and Welfare; Honoraria (self), Research grant / Funding (institution): Japanese Government of Environment. T. Kato: Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical Co. Ltd.; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb K.K.; Honoraria (self), Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Astellas; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self): Boehringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Chugai; Honoraria (self), Research grant / Funding (institution): Eli Lilly; Honoraria (self), Research grant / Funding (institution): Kyowa Kirin; Honoraria (self), Research grant / Funding (institution): Merck Sharp and Dohme; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Taiho; Honoraria (self): F. Hoffmann-La Roche; Honoraria (self), Research grant / Funding (institution): Merck Serono; Honoraria (self): Sumitomo Dainippon; Research grant / Funding (institution): Kyorin; Honoraria (self): Nitto Denko; Research grant / Funding (institution): Regeneron; Honoraria (self): Takeda. T. Iwasawa: Honoraria (self): Ono Pharmaceutical Co., Ltd.; Honoraria (self): Shionogi & Co., Ltd.; Honoraria (self): Nihon Medi-Physics Co., Ltd.; Honoraria (self): AstraZeneca K.K.; Honoraria (self): Boehringer Ingelheim Japan, Inc.; Honoraria (self): Bayer; Honoraria (self): GE Healthcare Japan; Research grant / Funding (institution): Tsuchiya Foundation ; Research grant / Funding (institution): KAKENHI; Honoraria (self): Canon Medical Systems; Honoraria (self): FujiFilm Medical Systems. H. Kenmotsu: Honoraria (self): Ono Pharmaceutical Co., Ltd; Honoraria (self): Bristol-Myers Squibb K.K.; Honoraria (self), Research grant / Funding (institution): AstraZeneca K.K.; Honoraria (self), Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Chugai Pharmacsutical Co, Ltd.; Honoraria (self): Eli Lilly K.K.; Honoraria (self): Kyowa Hakko Kirin Co., Ltd.; Honoraria (self): MSD K.K.; Honoraria (self): Novartis Pharma K.K.; Honoraria (self): Taiho Pharmaceutical Co, Ltd. M. Kusumoto: Advisory / Consultancy, Speaker Bureau / Expert testimony: Ono Pharmaceutical Co., Ltd.; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca K.K.; Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD K.K.; Research grant / Funding (institution): Canon Medical Systems Corporation. T. Baba: Honoraria (self): Ono Pharmaceutical Co., Ltd.; Honoraria (self): Bristol-Myers Squibb K.K.; Honoraria (self): AstraZeneca K.K.; Honoraria (self): Boston Scientific Japan Co., Ltd.; Honoraria (self): Nippon Boehringer Ingelheim Co., Ltd.; Honoraria (self): Daiichi Sankyo Co., Ltd.; Honoraria (self): Toray Industries, INC.; Honoraria (self): Shionogi & Co., Ltd.; Honoraria (self): Astellas Pharma Inc.; Honoraria (self): AMCO Inc; Honoraria (self): Asahi Kasei Pharma Corporation; Travel / Accommodation / Expenses: Kyorin Pharmaceutical Co., Ltd.; Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): MSD K.K. M. Endo: Advisory / Consultancy, Speaker Bureau / Expert testimony: Ono Pharmaceutical. Y. Fujiwara: Research grant / Funding (institution): AbbVie; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Research grant / Funding (institution): Chugai; Research grant / Funding (institution): Daiichi-Sankyo; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): Merck Serono; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): MSD; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Ono; Speaker Bureau / Expert testimony: Sysmex; Speaker Bureau / Expert testimony: Taiho. H. Sugiura: Advisory / Consultancy: Ono Pharmaceutical Co., Ltd.; Advisory / Consultancy: MSD K.K. N. Yanagawa: Honoraria (self): Ono Pharmaceutical Co., Ltd.; Honoraria (self): Miss Piggy Products; Advisory / Consultancy, Research grant / Funding (institution): Croak, Inc.; Research grant / Funding (institution), Non-remunerated activity/ies: Sunlight Stop. Inc. Y. Ito: Full / Part-time employment, Employee of the sponsor company: Ono Pharmaceutical Co., LTD. T. Sakamoto: Full / Part-time employment, Employee of the sponsor company: Ono Pharmaceutical Co., LTD. Y. Ohe: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Chugai; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Ono; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Kyorin; Advisory / Consultancy: Celltrion; Advisory / Consultancy: Amgen; Speaker Bureau / Expert testimony: Boehringer Ingelheim; Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Pfizer; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Taiho; Research grant / Funding (institution): Dainippon-Sumitomo; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Kissei; Research grant / Funding (institution): Daiichi-Sankyo; Research grant / Funding (institution): Janssen. K. Kuwano: Honoraria (self), Research grant / Funding (institution): Ono; Honoraria (self), Research grant / Funding (institution): Boehringer; Honoraria (self), Research grant / Funding (institution): Glaxo; Honoraria (self), Research grant / Funding (institution): Daiichi Sankyo; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Shionogi; Honoraria (self): Eisai; Honoraria (self), Research grant / Funding (institution): Chugai; Honoraria (self): MSD; Honoraria (self): Taiho; Honoraria (self), Research grant / Funding (institution): Astellas; Honoraria (self), Research grant / Funding (institution): Kyorin; Honoraria (self): Tsumura. All other authors have declared no conflicts of interest.
Resources from the same session
2036 - Salivary metabolomics for colorectal cancer detection
Presenter: Hiroshi Kuwabara
Session: Poster Display session 3
Resources:
Abstract
1868 - Evaluation and diagnostic potential of plasma biomarkers in bladder cancer
Presenter: Veronika Voronova
Session: Poster Display session 3
Resources:
Abstract
3655 - Liquid biopsy assays using combined circulating tumor cells and circulating tumor DNA in the same patients for the diagnosis of primary lung cancer
Presenter: Yongjoon Suh
Session: Poster Display session 3
Resources:
Abstract
3685 - Peripheral Cytotoxic T Cell Correlates with Tumor Mutational Burden and is Predictive for Progression Free Survival in Advanced Breast Cancer
Presenter: Xiao-ran Liu
Session: Poster Display session 3
Resources:
Abstract
1050 - Splenic Metabolic Activity as Biomarker in Cervical Cancer
Presenter: Emiel De Jaeghere
Session: Poster Display session 3
Resources:
Abstract
1413 - Identification of distinct subtypes revealing prognostic and therapeutic relevance in diffuse type gastric cancer
Presenter: Seon-Kyu Kim
Session: Poster Display session 3
Resources:
Abstract
2140 - Recurrence risk evaluation in stage IB/IIA gastric cancer with TP53 codon 72 polymorphisms
Presenter: Satoshi Nishizuka
Session: Poster Display session 3
Resources:
Abstract
1573 - Identification and validation of a prognostic 4 genes signature for hepatocellular carcinoma: integrated ceRNA network analysis
Presenter: Yongcong Yan
Session: Poster Display session 3
Resources:
Abstract
1196 - Plasma KIM-1 is associated with clinical outcomes after resection for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805)
Presenter: Wenxin Xu
Session: Poster Display session 3
Resources:
Abstract
2657 - Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting
Presenter: Katharina Nekolla
Session: Poster Display session 3
Resources:
Abstract